Bromocriptine mesylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for bromocriptine mesylate and what is the scope of freedom to operate?
Bromocriptine mesylate
is the generic ingredient in three branded drugs marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Ss Pharma, Aurobindo Pharma Usa, Padagis Us, Sandoz, and Veroscience, and is included in eight NDAs. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.Bromocriptine mesylate has thirty-two patent family members in thirteen countries.
There are eight drug master file entries for bromocriptine mesylate. Eight suppliers are listed for this compound.
Summary for bromocriptine mesylate
International Patents: | 32 |
US Patents: | 12 |
Tradenames: | 3 |
Applicants: | 8 |
NDAs: | 8 |
Drug Master File Entries: | 8 |
Finished Product Suppliers / Packagers: | 8 |
Raw Ingredient (Bulk) Api Vendors: | 53 |
Clinical Trials: | 6 |
Patent Applications: | 5,197 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price trends for bromocriptine mesylate |
What excipients (inactive ingredients) are in bromocriptine mesylate? | bromocriptine mesylate excipients list |
DailyMed Link: | bromocriptine mesylate at DailyMed |
Recent Clinical Trials for bromocriptine mesylate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Andrew Moshfeghi, MD, MBA | Phase 1/Phase 2 |
Case Western Reserve University | Phase 1/Phase 2 |
VeroScience | Phase 1 |
Pharmacology for bromocriptine mesylate
Drug Class | Ergot Derivative |
Medical Subject Heading (MeSH) Categories for bromocriptine mesylate
US Patents and Regulatory Information for bromocriptine mesylate
Expired US Patents for bromocriptine mesylate
International Patents for bromocriptine mesylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | 2019003619 | FORMULACIONES DE BROMOCRIPTINA. (BROMOCRIPTINE FORMULATIONS.) | ⤷ Try a Trial |
Japan | 2016026168 | 代謝障害の治療のためのドーパミン作動薬と第一相インスリン分泌促進薬の組合せ (COMBINATION OF DOPAMINE AGONIST AND FIRST PHASE SECRETAGOGUE FOR TREATMENT OF METABOLIC DISORDERS) | ⤷ Try a Trial |
European Patent Office | 3620155 | FORMULATIONS DE BROMOCRIPTINE (BROMOCRIPTINE FORMULATIONS) | ⤷ Try a Trial |
Japan | 2015515984 | ブロモクリプチン製剤 | ⤷ Try a Trial |
Australia | 2013256558 | Bromocriptine formulations | ⤷ Try a Trial |
China | 102458376 | Combination of dopamine agonists plus first phase insulin secretagouges for treatment of metabolic disorders | ⤷ Try a Trial |
Uruguay | 34776 | FORMULACIONES DE BROMOCRIPTINA | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.